Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115231 · ClinicalTrials.gov registry record
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
A clinical trial of Macular Degeneration, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 223
- Enrollment target
- 2
- Study locations
NCT01115231: Completed study of Macular Degeneration, sponsored by VA Office of Research and Development.
NCT01115231 is a study of Macular Degeneration that has completed, run by VA Office of Research and Development. The registered enrollment target is 223 participants, above the 171-participant average among 26 other Macular Degeneration trials with a reported enrollment target (30% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01115231, a study of Macular Degeneration, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
- 2
- Study locations
Study Summary
Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system. Smoking is the only environmental factor known to increase the risk of Age-related Macular Degeneration (AMD). Using serum samples of Age-related Macular Degeneration (AMD) patients and controls the investigators will test the hypothesis that smoking increases Age-related Macular Degeneration (AMD) by increasing complement activation; and that this is positively correlated with known disease variations in the complement factor H (CFH) gene.
Primary Outcome
Assessment of Age based on clinical records.
Conditions Studied
Study Locations (2)
South Carolina
- Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-12-31 |
What the finished NCT01115231 record still lists
NCT01115231 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, above the 171-participant average among 26 other Macular Degeneration trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.
NCT01115231 reports a single indexed study location in South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01115231 about?
NCT01115231 is a clinical study titled "Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration". Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system. Smoking is the only environmental factor known to increase the risk of Age-related ...
What is the current status of trial NCT01115231?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2010-10. Estimated completion is 2016-12-31.
What conditions does trial NCT01115231 study?
This clinical trial studies the following conditions: Macular Degeneration.
Who is sponsoring clinical trial NCT01115231?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115231 being conducted?
This trial has 2 study locations across South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01115231's enrollment target sits among peer trials
223 7th of 26 higher than 20 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
-
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
RECRUITING
-
Factors in Learning And Plasticity: Healthy Vision
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia